Selegiline in the treatment of Parkinson's disease — long term experience

M. D. Yahr, T. S. Elizan, D. Moros

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Abstract– L‐deprenyl (selegiline) has been reported as a safe effective adjunctive agent to levodopa in the control of Parkinson's symptoms, as well as a means of preventing the progressive nature of the disease process. In an ongoing study, now in its 12th year, L‐deprenyl has been administered 1. as monotherapy or 2. in combination with levodopa, to previously untreated patients in the early phases of the disease; 3. added to an existing regimen of levodopa when optimal therapeutic results are not being obtained. This report reviews our experience in each of these three treatment categories. Results obtained to date, indicate that L‐deprenyl administered alone does not prevent the occurrence of signs of Parkinson's disease. It's administration with levodopa, as initial therapy, allows for use of lower dosage and less side effects of the latter agent. When L‐deprenyl is added to sub‐optimal responders to levodopa, it attenuates fluctuating responses, particularly those of the ‘end‐of‐dose’variety.

Original languageEnglish
Pages (from-to)157-161
Number of pages5
JournalActa Neurologica Scandinavica
StatePublished - Nov 1989


  • Parkinson's disease
  • Selegiline
  • fluctuations in disability
  • long term therapy


Dive into the research topics of 'Selegiline in the treatment of Parkinson's disease — long term experience'. Together they form a unique fingerprint.

Cite this